Marc B. Blaustein

Mr. Blaustein is a 17-year biotechnology industry veteran with experience spanning executive management, product development, business development, and line function leadership. He was the founding CEO of Halo Therapeutics, now part of Akashi. Mr. Blaustein has led development efforts for two products that were approved by FDA and subsequently launched commercially, and has closed numerous deals for biotechnology products, technologies, and services. Previously, he was a Senior Vice President at Dyax Corp where he led departments including Manufacturing, Program Management, Commercial Operations, and Alliance Management. Before that, he held positions of increasing responsibility at Alkermes and Genetics Institute (now Pfizer). Mr. Blaustein holds a Master’s Degree from Harvard University and a B.A. in Biology from the University of Pennsylvania.